ArticleNature2020
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 505 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
505citing papers in PubMed, 2 pooled it
18.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
505 citing papers in PubMed, 2 syntheses or guidelines pooled it, 849 citations in OpenAlex.
- The pharmacological properties and corresponding mechanisms of farrerol: a comprehensive review.Pharmaceutical biology · 2022Pooled it
- Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules.International journal of molecular sciences · 2022Pooled it
- Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials.Scientific reports · 2025Trial
- Trial
- PI(3,5)PScience advances · 2026Article
- Convergent use of aminopeptidase N receptor by hedgehog merbecoviruses.Nature microbiology · 2026Article
- Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions.Metabolic brain disease · 2026Review
- Native Label-Free Spectral Biochemical Fingerprinting of an Enveloped Mammalian RNA Virus Reveals Mode of Action of a Virucidal Drug.Small methods · 2026Article
- A host-centric morphological profiling approach to identify repurposed antiviral drugs.iScience · 2026Article
- The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages.International journal of molecular sciences · 2026Article
- The architecture of computational antiviralism: a multi-scale framework from molecular targeting to viral ecosystem engineering.Molecular diversity · 2026Review
- Reimagining human-centric drug development with new approach methodologies.Science (New York, N.Y.) · 2026Review
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia.Signal transduction and targeted therapy · 2026Article
- Article
- Epitranscriptomic signatures of m5C, m6A, and pseudouridine in COVID-19 reveal host RNA modifications involved in viral pathogenesis.Microbiology spectrum · 2026Article
- Article
- Integrated phenotypic screening and chemical proteomics identifies ETF1 ligands that modulate viral translation and replication.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes.Journal of advanced research · 2026Article
- Drug-induced phospholipidosis as an artifact in antiviral drug repurposing.bioRxiv : the preprint server for biology · 2025Article
- Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.Journal of virology · 2025Article
445 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
45 authors at 13 institutions in 3 countries.
Laura Riva *Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Shuofeng Yuan *State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Xin YinImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-2357-6718
Laura Martin-SanchoImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Naoko MatsunagaImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Lars PacheImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4193-1042
Sebastian Burgstaller-MuehlbacherCenter for Integrative Bioinformatics Vienna, Max Perutz Laboratories, University of Vienna and Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-4640-3510
Paul D De JesusImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Peter TerieteImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Mitchell V HullCalibr at Scripps Research, La Jolla, CA, USA.
Max W ChangDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jasper Fuk-Woo ChanState Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Jianli CaoState Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Vincent Kwok-Man PoonState Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Kristina M HerbertImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Kuoyuan ChengCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Tu-Trinh H NguyenCalibr at Scripps Research, La Jolla, CA, USA.
Andrey RubanovImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Yuan PuImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Courtney NguyenImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Angela ChoiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raveen RathnasingheDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-3156-3132
Lisa MiorinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marion DejosezHuffington Foundation Center for Cell-based Research in Parkinson's Disease, Department for Cell, Regenerative and Developmental Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thomas P ZwakaHuffington Foundation Center for Cell-based Research in Parkinson's Disease, Department for Cell, Regenerative and Developmental Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ko-Yung SitDepartment of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, TX, USA.ORCID http://orcid.org/0000-0001-7084-0804
Wen-Chun LiuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kris M WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0889-0506
Mackenzie E ChapmanDepartment of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Emma K LendyDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.
Richard J GlynneInception Therapeutics, San Diego, CA, USA.
Randy AlbrechtDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4008-503X
Eytan RuppinCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Andrew D MesecarDepartment of Biological Sciences, Purdue University, West Lafayette, IN, USA.ORCID http://orcid.org/0000-0002-1241-2577
Jeffrey R JohnsonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Christopher BennerDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Ren SunDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8628-7019
Peter G SchultzCalibr at Scripps Research, La Jolla, CA, USA.
Andrew I SuDepartment of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9859-4104
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6551-1827
Arnab K ChatterjeeCalibr at Scripps Research, La Jolla, CA, USA. achatterjee@scripps.edu.ORCID http://orcid.org/0000-0001-5171-7982
Kwok-Yung YuenState Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China. kyyuen@hku.hk.ORCID http://orcid.org/0000-0002-2083-1552
Sumit K ChandaImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. schanda@sbpdiscovery.org.ORCID http://orcid.org/0000-0001-9399-7927
Sanford Burnham Prebys Medical Discovery Institute · USIcahn School of Medicine at Mount Sinai · USUniversity of Hong Kong · HKPurdue University West Lafayette · USScripps Institution of Oceanography · USNational Cancer Institute · USNew York Stem Cell Foundation · USScripps Research Institute · USUniversity of California San Diego · USHKU-Pasteur Research Pole · HKMax Perutz Labs · ATTexas Biomedical Research Institute · USUniversity of California, Los Angeles · US
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MProject 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HARRIS, EVA · 2015 to 2021
$46.6MSARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MTechnology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Adolfo Garcia-Sastre, Anna Karolina Palucka · 2019 to 2026
$23.1MDiscovering Affective Drug Combinations for Treating Covid-19ZIABC012000 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUPPIN, EYTAN · 2020 to 2022
$2.3MPurdue University Molecular Biophysics Training ProgramT32GM132024 · NIGMS · PURDUE UNIVERSITY · PI Angeline Marie Lyon, John Tesmer · 2019 to 2026
$2.0MNCI NIH HHS P30 CA023100NCI NIH HHS P30 CA030199NIAID NIH HHS HHSN272201400008CNIAID NIH HHS HHSN272201700060CNIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI135972NIAID NIH HHS U19 AI142733NIGMS NIH HHS T32 GM132024
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19)
Indexed as
Drug Evaluation, PreclinicalDrug RepositioningAdenosine MonophosphateAlanineAlveolar Epithelial CellsAntiviral AgentsBetacoronavirusCell LineCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentCysteine Proteinase InhibitorsDose-Response Relationship, DrugDrug SynergismGene Expression RegulationHumansAdenosine MonophosphateAlanineAntiviral AgentsapilimodCysteine Proteinase InhibitorsHydrazonesMorpholinesPyrimidinesremdesivirSmall Molecule LibrariesTriazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.